Down-regulation of the dual-specificity phosphatase MKP-1 suppresses tumorigenicity of pancreatic cancer cells

Gastroenterology

Volumn 124, Issue 7, 2003, Pages 1830-1845

  Liao, Quan ^a,b,c   Guo, Junchao ^a,c   Kleeff, Jörg ^a,b   Zimmermann, Arthur ^d   Büchler, Markus W ^a,b   Korc, Murray ^e   Friess, Helmut ^a,b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b Department of Visceral Surgery ^*  (Switzerland)

^c PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^d UNIVERSITY OF BERN   (Switzerland)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH FACTOR; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE PHOSPHATASE 1; MITOGENIC AGENT; PHOSPHATASE; TYROSINE KINASE RECEPTOR; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ANCHORAGE INDEPENDENT GROWTH; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CANCER INHIBITION; CARCINOGENICITY; CHRONIC PANCREATITIS; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; ENZYME REGULATION; ENZYME REPRESSION; ENZYME SPECIFICITY; FEMALE; GENE EXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MALE; MOUSE; NONHUMAN; NORTHERN BLOTTING; NUCLEOTIDE SEQUENCE; NUDE MOUSE; PANCREAS CANCER; PANCREAS TUMOR; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

EID: 0037606170     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0016-5085(03)00398-6     Document Type: Article

References (46)

1. Kazama H, Yonehara S. Oncogenic K-Ras and basic fibroblast growth factor prevent Fas-mediated apoptosis in fibroblasts through activation of mitogen-activated protein kinase. J Cell Biol 2000;148:557-566.
2. Crews CM, Erikson RL. Extracellular signals and reversible protein phosphorylation: what to Mek of it all. Cell 1993;74:215-217.
3. Pelech SL, Sanghera JS. MAP kinases: charting the regulatory pathways. Science 1992;257:1355-1356.
4. Wu J, Harrison JK, Vincent LA, Haystead C, Haystead TA, Michel H, Hunt DF, Lynch KR, Sturgill TW. Molecular structure of a protein-tyrosine/threonine kinase activating p42 mitogen-activated protein (MAP) kinase: MAP kinase kinase. Proc Natl Acad Sci U S A 1993;90:173-177.
5. Guyton KZ, Gorospe M, Kensler TW, Holbrook NJ. Mitogen-activated protein kinase (MAPK) activation by butylated hydroxytoluene hydroperoxide: implications for cellular survival and tumor promotion. Cancer Res 1996;56:3480-3485.
6. Zheng CF, Guan KL. Cloning and characterization of two distinct human extracellular signal-regulated kinase activator kinases, MEK1 and MEK2. J Biol Chem 1993;268:11435-11439.
7. Misra-Press A, Rim CS, Yao H, Roberson MS, Stork PJ. A novel mitogen-activated protein kinase phosphatase. Structure, expression, and regulation. J Biol Chem 1995;270:14587-14596.
8. Sun H, Charles CH, Lau LF, Tonks NK. MKP-1 (3CH134), an immediate early gene product, is a dual specificity phosphatase that dephosphorylates MAP kinase in vivo. Cell 1993;75:487-493.
9. Franklin CC, Srikanth S, Kraft AS. Conditional expression of mitogen-activated protein kinase phosphatase-1, MKP-1, is cytoprotective against UV-induced apoptosis. Proc Natl Acad Sci U S A 1998;95:3014-3019.
10. Mayr M, Li C, Zou Y, Huemer U, Hu Y, Xu Q. Biomechanical stress-induced apoptosis in vein grafts involves p38 mitogen-activated protein kinases. FASEB J 2000;14:261-270.
11. Srikanth S, Franklin CC, Duke RC, Kraft RS. Human DU145 prostate cancer cells overexpressing mitogen-activated protein kinase phosphatase-1 are resistant to Fas ligand-induced mitochondrial perturbations and cellular apoptosis. Mol Cell Biochem 1999;199:169-178.
12. Loda M, Capodieci P, Mishra R, Yao H, Corless C, Grigioni W, Wang Y, Magi-Galluzzi C, Stork PJ. Expression of mitogen-activated protein kinase phosphatase-1 in the early phases of human epithelial carcinogenesis. Am J Pathol 1996;149:1553-1564.
13. Bang YJ, Kwon JH, Kang SH, Kim JW, Yang YC. Increased MAPK activity and MKP-1 overexpression in human gastric adenocarcinoma. Biochem Biophys Res Commun 1998;250:43-47.
14. Alanen KA, Joensuu H. Long-term survival after pancreatic adenocarcinoma - often a misdiagnosis? Br J Cancer 1993;68:1004-1005.
15. Tsiotos GG, Farnell MB, Sarr MG. Are the results of pancreatectomy for pancreatic cancer improving? World J Surg 1999;23:913-919.
16. Almoguera C, Shibata D, Forrester K, Martin J, Arnheim N, Perucho M. Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 1988;53:549-554.
17. Grunewald K, Lyons J, Frohlich A, Feichtinger H, Weger RA, Schwab G, Janssen JW, Bartram CR. High frequency of Ki-ras codon 12 mutations in pancreatic adenocarcinomas. Int J Cancer 1989;43:1037-1041.
18. Casey G, Yamanaka Y, Friess H, Kobrin MS, Lopez ME, Buchler M, Beger HG, Korc M. p53 mutations are common in pancreatic cancer and are absent in chronic pancreatitis. Cancer Lett 1993;69:151-160.
19. Yokoyama M, Yamanaka Y, Friess H, Buchler M, Korc M. p53 expression in human pancreatic cancer correlates with enhanced biological aggressiveness. Anticancer Res 1994;14:2477-2483.
20. Hahn SA, Schutte M, Hoque AT, Moskaluk CA, da Costa LT, Rozenblum E, Weinstein CL, Fischer A, Yeo CJ, Hruban RH, Kern SE. DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science 1996;271:350-353.
21. Korc M. Role of growth factors in pancreatic cancer. Surg Oncol Clin N Am 1998;7:25-41.
22. Ozawa F, Friess H, Tempia-Caliera A, Kleeff J, Buchler MW. Growth factors and their receptors in pancreatic cancer. Teratog Carcinog Mutagen 2001;21:27-44.
23. Adler G, Schmid RM. Chronic pancreatitis: still puzzling? Gastroenterology 1997;112:1762-1765.
24. Kleeff J, Friess H, Korc M, Buchler MW. Chronic pancreatitis: pathogenesis and molecular aspects. Ann Ital Chir 2000;71:3-10.
25. Liebmann C. Regulation of MAP kinase activity by peptide receptor signalling pathway: paradigms of multiplicity. Cell Signal 2001;13:777-785.
26. Kleeff J, Ishiwata T, Kumbasar A, Friess H, Buchler MW, Lander AD, Korc M. The cell-surface heparan sulfate proteoglycan glypican-1 regulates growth factor action in pancreatic carcinoma cells and is overexpressed in human pancreatic cancer. J Clin Invest 1998;102:1662-1673.
27. Friess H, Yamanaka Y, Buchler M, Ebert M, Beger HG, Gold LI, Korc M. Enhanced expression of transforming growth factor beta isoforms in pancreatic cancer correlates with decreased survival. Gastroenterology 1993;105:1846-1856.
28. Friess H, Yamanaka Y, Buchler M, Berger HG, Kobrin MS, Baldwin RL, Korc M. Enhanced expression of the type II transforming growth factor beta receptor in human pancreatic cancer cells without alteration of type III receptor expression. Cancer Res 1993;53:2704-2707.
29. Koliopanos A, Friess H, Kleeff J, Shi X, Liao Q, Pecker I, Vlodavsky I, Zimmermann A, Buchler MW. Heparanase expression in primary and metastatic pancreatic cancer. Cancer Res 2001;61:4655-4659.
30. Kornmann M, Arber N, Korc M. Inhibition of basal and mitogen-stimulated pancreatic cancer cell growth by cyclin D1 antisense is associated with loss of tumorigenicity and potentiation of cytotoxicity to cisplatinum. J Clin Invest 1998;101:344-352.
31. Baldwin RL, Korc M. Growth inhibition of human pancreatic carcinoma cells by transforming growth factor beta-1. Growth Factors 1993;8:23-34.
32. Raitano AB, Korc M. Tumor necrosis factor up-regulates gammainterferon binding in a human carcinoma cell line. J Biol Chem 1990;265:10466-10472.
33. Kleeff J, Kornmann M, Sawhney H, Korc M. Actinomycin D induces apoptosis and inhibits growth of pancreatic cancer cells. Int J Cancer 2000;86:399-407.
34. Davis RJ. The mitogen-activated protein kinase signal transduction pathway. J Biol Chem 1993;268:14553-14556.
35. Whitmarsh AJ, Shore P, Sharrocks AD, Davis RJ. Integration of MAP kinase signal transduction pathways at the serum response element. Science 1995;269:403-407.
36. Liu Y, Guyton KZ, Gorospe M, Xu Q, Kokkonen GC, Mock YD, Roth GS, Holbrook NJ. Age-related decline in mitogen-activated protein kinase activity in epidermal growth factor-stimulated rat hepatocytes. J Biol Chem 1996;271:3604-3607.
37. Ward Y, Gupta S, Jensen P, Wartmann M, Davis RJ, Kelly K. Control of MAP kinase activation by the mitogen-induced threonine/tyrosine phosphatase PAC1. Nature 1994;367:651-654.
38. Traverse S, Gomez N, Paterson H, Marshall C, Cohen P. Sustained activation of the mitogen-activated protein (MAP) kinase cascade may be required for differentiation of PC12 cells. Comparison of the effects of nerve growth factor and epidermal growth factor. Biochem J 1992;288:351-355.
39. Qui MS, Green SH. PC12 cell neuronal differentiation is associated with prolonged p21ras activity and consequent prolonged ERK activity. Neuron 1992;9:705-717.
40. Marshall CJ. Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation. Cell 1995;80:179-185.
41. Charles CH, Abler AS, Lau LF. cDNA sequence of a growth factor-inducible immediate early gene and characterization of its encoded protein. Oncogene 1992;7:187-190.
42. Sun H, Tonks NK, Bar-Sagi D. Inhibition of Ras-induced DNA synthesis by expression of the phosphatase MKP-1. Science 1994;266:285-288.
43. Goillot E, Raingeaud J, Ranger A, Tepper RI, Davis RJ, Harlow E, Sanchez I. Mitogen-activated protein kinase-mediated Fas apoptotic signaling pathway. Proc Natl Acad Sci U S A 1997;94:3302-3307.
44. 2. Am J Physiol 1997;273:L1029-L1035.
45. Chen YR, Wang X, Templeton D, Davis RJ, Tan TH. The role of c-Jun N-terminal kinase (JNK) in apoptosis induced by ultraviolet C and gamma radiation. Duration of JNK activation may determine cell death and proliferation. J Biol Chem 1996;271:31929-31936.
46. Bhalla US, Ram PT, Iyengar R. MAP kinase phosphatase as a locus of flexibility in a mitogen-activated protein kinase signaling network. Science 2002;297:1018-1023.